Navigation Links
MSU launches groundbreaking drug trial in Africa
Date:2/15/2013

Determined to bring relief to seizure victims, a Michigan State University research team this month begins a groundbreaking clinical drug trial that could help prevent a quarter-million African children from developing epilepsy each year.

It will be the first test of the anti-seizure medication levetiracetam, or LVT, for controlling seizures caused by cerebral malaria, a severe form of the disease that affects brain function in some three million children, mostly in sub-Saharan Africa.

About one in 10 children who survive cerebral malaria are left with epileptic seizures, said the trial's lead researcher Gretchen Birbeck, a professor of neurology and ophthalmology in the College of Osteopathic Medicine.

"This trial is aimed at improving seizure control with the hope of finding a path toward epilepsy prevention," Birbeck said. "Since oral LVT is relatively affordable for short-term use and feasibly could be delivered in resource-limited settings, this therapy could potentially be scaled up for broad use throughout malaria endemic African countries."

The trial will include about 40 children in Malawi. If all safety standards are met, dosage will be increased until 75 percent of the children are free of seizures for 24 hours.

A wireless EEG monitoring device the size of a deck of cards will tell the researchers if LVT is keeping the children seizure-free. Developed by New York-based biotechnology firm BioSignal Group, the device can be worn on the child's arm and transfers data in real-time to a computer, where it quickly can be analyzed and shared with colleagues.

"Unfortunately, many children with cerebral malaria continue to have seizures with no clinical evidence that seizures are occurring, but their brains still are being affected," said Birbeck, who also is director of MSU's International Neurologic and Psychiatric Epidemiology Program. "To evaluate the effectiveness of LVT, we need continuous EEG monitoring, which is very tough to do even in the best environment."

If the study finds a safe and effective dosage of LVT for cerebral malaria seizures, the team will scale it up and put the drug to the test in a randomized trial without the specialized technology.

The trial, part of MSU's Blantyre Malaria Project at Queen Elizabeth Central Hospital, is being funded with a nearly $2 million grant from the National Institutes of Health's National Institute of Neurological Disorders and Stroke.

It's part of a broader effort by Birbeck to, as she says, "bring epilepsy out of the shadows." The disease keeps many of its victims from holding a job or going to school, and the stigma associated with seizures prevent many of them from getting the treatment they need.

Birbeck is working in Malawi and Zambia to educate people about the disease so they aren't afraid to seek treatment. With her help, more and more patients are getting help and living productive lives.

Her ultimate goal is to find a way to keep people from getting epilepsy in the first place.

"The best legacy would be when they didn't need epilepsy treatment," she said. "That would be the nicest of all."


'/>"/>

Contact: Andy McGlashen
andy.mcglashen@cabs.msu.edu
517-355-5158
Michigan State University
Source:Eurekalert

Related biology news :

1. NTU launches new centre to develop new eye-deas for occular therapeutics
2. Elsevier launches new open access journal: Molecular Metabolism
3. Canada launches first gene therapy trial for Fabry disease
4. Elsevier launches new journal: Journal of Unconventional Oil and Gas Resources
5. F1000Research, the first Open Science publisher, launches following a successful beta testing phase
6. Wake Forest Baptist Medical Center Launches Wake Forest Innovations
7. Neurotechnology Launches SkyBiometry Spin-off Company to Deliver SaaS Biometric Identification and Feature Analysis
8. Elsevier launches new open access journal -- Case Studies in Engineering Failure Analysis
9. Gene sequencing project identifies abnormal gene that launches rare childhood leukemia
10. Smithsonian launches global marine biodiversity project with $10 million donation
11. Rice launches sweeping Energy and Environment Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... PRAGUE, Czech Republic , February 8, 2016 ... first EU-regulated global payment platform which presents innovation ... Voice Biometrics Authentication feature called VoiceKey. --> ... payment platform which presents innovation for clients, comfort ... feature called VoiceKey. --> Worldcore ...
(Date:2/3/2016)... --> --> ... Fingerprint Identification System Market by Component (Hardware and Software), ... Finance, Government, Healthcare, and Transportation) and Geography - Global ... expected to be worth USD 8.49 Billion by 2020 ... 2020. The transformation and technology evolution from the manual ...
(Date:2/2/2016)... , Feb. 2, 2016 This BCC ... bioinformatic market by reviewing the recent advances in ... that drive the field forward. Includes forecast through ... Identify the challenges and opportunities that exist in ... software solution developers, as well as IT and ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... ... 11, 2016 , ... Global Stem Cells Group, ... Global Stem Cells Network (GSCN) to distribute exosome injection and other biological products ... Costa Rica, Dominican Republic, Colombia, Argentina, Nicaragua, Panama, El Salvador, Venezuela, Peru, Ecuador, ...
(Date:2/10/2016)... NX Prenatal Inc., a US based ... for early warning of adverse pregnancy outcomes, announced ... by Dr. Thomas McElrath of Brigham ... Medicine,s (SMFM) annual meeting held in ... The presentation reported initial positive top-line results regarding ...
(Date:2/10/2016)... , Feb. 10, 2016  Matchbook, Inc., ... for fast growing biotech companies, announced today the ... Procurement Strategic Advisor. Jim brings nearly 25 years ... and procurement, having spent nearly two decades in ... Chain/Logistics and Procurement at Genzyme and, most recently ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... a research registry built on the secure online PatientCrossroads platform, has exceeded both ... 1,600 participants have joined the PROMPT study, which seeks to advance understanding of ...
Breaking Biology Technology: